# JCO2 Rec'd PCT/PTC

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

QE	IAP	\
6	2015	E I
ં લ્હ	0,	8
\'.	1.6	<b>\$</b>
TIEN	T & PASS	

TRANSMITTAL **FORM** 

(to be used for all correspondence after initial filing)

Alexandria, VA 22313-1450 on the date shown below.

Laleh/Shayesteh

Signature

Typed or printed name

Total Number of Pages in This Submission

**Application Number** 10/535,447 May 19, 2005 Filing Date First Named Inventor Tai Art Unit **Examiner Name** Attorney Docket Number EX03-086C-US

	ENCLOSURES (check all that app	ly)
Fee Transmittal Form	☐ Drawing(s)	After Allowance Communication to TC
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences
Amendment / Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After Final	Petition to Convert to a Provisional Application	Proprietary Information
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter
Extension of Time Request	Terminal Disclaimer	Other Enclosure(s) (please identify below):
Express Abandonment Request	Request for Refund CD, Number of CD(s)	Reference copies Return Receipt Postcard
Information Disclosure Statement	☐ Landscape Table on CD	
Certified Copy of Priority Document(s)	Remarks	
Reply to Missing Parts/		
Incomplete Application		
Reply to Missing Parts		
under 37 CFR1.52 or 1.53		
SIGN	IATURE OF APPLICANT, ATTORNEY	, OR AGENT
Firm	EXELIXIS, INC.	•
Signature	(AM)	
Printed Name	Laleh Shayesteh	
Date	August 30, 2005 Reg No.	47,937
	CERTIFICATE OF TRANSMISSION/	MAILING

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450,

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Date

August 30, 2005



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Patent Application of Tai et al.

Application No.: 10/535,447

Filed: May 19, 2005

For: CCT6S AS MODIFIERS OF THE RB

PATHWAY AND METHODS OF USE

Confirmation No.: 8814

Art Unit: Not Assigned

Examiner: Not Assigned

Attorney Docket No.: EX03-086C-US

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

The GENESEQ® database was queried to identify sequences that are identical or related to the sequences recited in the claims of the above-referenced patent application. The following patent publications were identified:

WO0055174, Human Genome Sciences, September 21, 2000 WO0246465, OXFORD BIOMEDICA (UK) LIMITED, June 13, 2002 WO9520654, THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL, August 3, 1995

The above-references have <u>not</u> been reviewed to assess whether they are material to the patentability of the claimed invention; nor have they been reviewed to assess whether they are substantively cumulative to the disclosures of the references cited in and provided with the "Information Disclosure Statement by Applicant" filed simultaneously herewith.

Upon request, Applicants will gladly obtain copies of any of these references and forward them to the Examiner for consideration.

Respectfully submitted,

Dated: August 30, 2005

Laleh Shayesteh

Reg. No. 47,937

Tel: (650) 837-8223; Fax: (650) 837-8234



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Tai et al.

Application No.: 10/535,447

Filed: May 19, 2005

For: CCT6S AS MODIFIERS OF THE RB

PATHWAY AND METHODS OF USE

Confirmation No.: 8814

Art Unit: Not Assigned

Examiner: Not Assigned

Attorney Docket No.: EX03-086C-US

#### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In accordance with 37 C.F.R §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

In accordance with 37 C.F.R §1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 C.F.R. §1.56 exists.

In accordance with 37 C.F.R §1.97 (h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

The Commissioner is hereby authorized to charge any required fees, if necessary, to Deposit No. 50-1108.

Respectfully submitted,

Dated: August 30, 2005

Laleh Shayesteh

Reg. No. 47,937

Tel: (650) 837-8223; Fax: (650) 837-8234



PTO/SB/08b(08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 10/535,447 Application Number Filing Date May 19, 2005 First Named Inventor Tai Art Unit Examiner Name EX03-086C-US

(Use as many sheets as necessary)

Sheet Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Hillier,L.W., et al. Homo sapiens chaperonin containing TCP1, subunit 6A (zeta 1) (CCT6A), mRNA. GI:22095341 22-NOV-2004	
	2	Lee, YK. and Yoo, YD. Homo sapiens heat shock protein mRNA, complete cds. Gl:14348899 12-JUN-2001	
•	3	Wang,H., et al. Homo sapiens MoDP-2, MoDP-3 mRNA for acute morphine dependence related protein 2, acute morphine dependence related peptide 3, complete cds. GI:14517631 09-AUG-2001	
····	4	Kubota,H., et al. Homo sapiens chaperonin containing TCP1, subunit 6B (zeta 2) (CCT6B), mRNA. GI:5729760 03-SEP-2004	
	5	NCBI Annotation Project. Homo sapiens chaperonin containing TCP1, subunit 6B (zeta 2) (CCT6B), mRNA. GI:14771917 01-AUG-2002	
	6	Ozaki,K., et al. Homo sapiens mRNA for testis-specific TCP20, complete cds. Gl:1655415 09-FEB-2005	
	7	Strausberg,R.L., et al. Homo sapiens chaperonin containing TCP1, subunit 6B (zeta 2), mRNA (cDNA clone MGC:34021 IMAGE:4822253), complete cds. GI:34783247 28-JUL-2005	
	8	Yokota,S., et al. chaperonin containing TCP1, subunit 6A isoform a [Homo sapiens]. GI:4502643 23-APR-2005	
<del> </del>	9	Kubota,H., et al. chaperonin containing TCP1, subunit 6B (zeta 2) [Homo sapiens]. GI:5729761 03-SEP-2004	
		-	

Examiner Signature /Misook Yu/ Date Considered 04/19/2009
---

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.